- Clinical Trials
- January 2024
- 60 Pages
Global
From €1907EUR$2,000USD£1,625GBP
- Clinical Trials
- January 2024
- 100 Pages
Global
From €1907EUR$2,000USD£1,625GBP
- Report
- May 2024
- 134 Pages
Global
From €6196EUR$6,499USD£5,281GBP
- Report
- June 2024
- 898 Pages
Global
From €5339EUR$5,600USD£4,551GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1192EUR$1,250USD£1,016GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1192EUR$1,250USD£1,016GBP
- Clinical Trials
- January 2024
- 80 Pages
Global
From €1907EUR$2,000USD£1,625GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1192EUR$1,250USD£1,016GBP
- Report
- September 2022
- 30 Pages
Global
From €2622EUR$2,750USD£2,235GBP
- Report
- August 2022
- 30 Pages
Global
From €3098EUR$3,250USD£2,641GBP
- Report
- January 2021
- 32 Pages
Global
€1257EUR$1,318USD£1,071GBP
- Report
- May 2019
- 84 Pages
Global
From €6669EUR$6,995USD£5,684GBP
- Drug Pipelines
- August 2019
- 54 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Drug Pipelines
- June 2018
- 43 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Report
- March 2024
- 96 Pages
Global
From €3500EUR$3,933USD£3,088GBP
- Report
- October 2023
- 78 Pages
Global
From €3500EUR$3,933USD£3,088GBP
- Report
- May 2022
- 95 Pages
Global
From €3500EUR$3,933USD£3,088GBP
- Report
- December 2022
- 42 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Report
- October 2022
- 57 Pages
Global
From €3337EUR$3,500USD£2,844GBP
- Report
- October 2022
- 69 Pages
Global
From €3337EUR$3,500USD£2,844GBP
The Glutamate Receptor market is a subset of the Central Nervous System Drugs market. Glutamate Receptors are proteins found in the brain and are responsible for the majority of excitatory neurotransmission. They are involved in a variety of neurological processes, including learning, memory, and cognition. As such, they are a target for drug development, with the aim of treating neurological disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy.
The Glutamate Receptor market is highly competitive, with a number of large pharmaceutical companies and biotechnology firms vying for market share. Companies in the market include Merck, Pfizer, Novartis, Eli Lilly, and AstraZeneca. Additionally, there are a number of smaller companies, such as Neurocrine Biosciences, that are developing drugs targeting Glutamate Receptors. Show Less Read more